Viatris Sells Tyrvaya for Up to $100M, Lifts 2026 Guidance
VTRS sits 96% above its 52-week low of $8.735.
Summary
Viatris is selling its dry-eye drug Tyrvaya to Harrow for up to $100 million — $30 million cash upfront plus $70 million in sales milestones. The deal sharpens the company's focus on complex generics and transdermal products. Alongside the divestiture, Viatris raised its full-year 2026 adjusted EPS guidance to $2.45–$2.49 (from $2.33–$2.47) and revenue to $14.55B–$14.95B (from $14.45B–$14.95B), both above consensus. This follows this morning's Q2 beat of $3.76B revenue and $0.69 EPS, reinforcing the turnaround narrative. The stock fell 4% on the day, likely reflecting profit-taking after the strong quarter.
At the time of this announcement, VTRS was trading at $17.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.1B. The 52-week trading range was $8.74 to $18.39. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.